IBDEI2LG ; ; 17-FEB-2016
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,44035,0)
 ;;=B35.1^^170^2116^22
 ;;^UTILITY(U,$J,358.3,44035,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,44035,1,3,0)
 ;;=3^Tinea Unguium
 ;;^UTILITY(U,$J,358.3,44035,1,4,0)
 ;;=4^B35.1
 ;;^UTILITY(U,$J,358.3,44035,2)
 ;;=^119748
 ;;^UTILITY(U,$J,358.3,44036,0)
 ;;=L03.90^^170^2116^3
 ;;^UTILITY(U,$J,358.3,44036,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,44036,1,3,0)
 ;;=3^Cellulitis,Unspec
 ;;^UTILITY(U,$J,358.3,44036,1,4,0)
 ;;=4^L03.90
 ;;^UTILITY(U,$J,358.3,44036,2)
 ;;=^5009067
 ;;^UTILITY(U,$J,358.3,44037,0)
 ;;=L03.91^^170^2116^6
 ;;^UTILITY(U,$J,358.3,44037,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,44037,1,3,0)
 ;;=3^Lymphangitis,Acute,Unspec
 ;;^UTILITY(U,$J,358.3,44037,1,4,0)
 ;;=4^L03.91
 ;;^UTILITY(U,$J,358.3,44037,2)
 ;;=^5009068
 ;;^UTILITY(U,$J,358.3,44038,0)
 ;;=L25.9^^170^2116^4
 ;;^UTILITY(U,$J,358.3,44038,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,44038,1,3,0)
 ;;=3^Contact Dermatitis,Unspec Cause
 ;;^UTILITY(U,$J,358.3,44038,1,4,0)
 ;;=4^L25.9
 ;;^UTILITY(U,$J,358.3,44038,2)
 ;;=^5133647
 ;;^UTILITY(U,$J,358.3,44039,0)
 ;;=L40.0^^170^2116^17
 ;;^UTILITY(U,$J,358.3,44039,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,44039,1,3,0)
 ;;=3^Psoriasis Vulgaris
 ;;^UTILITY(U,$J,358.3,44039,1,4,0)
 ;;=4^L40.0
 ;;^UTILITY(U,$J,358.3,44039,2)
 ;;=^5009160
 ;;^UTILITY(U,$J,358.3,44040,0)
 ;;=L40.2^^170^2116^1
 ;;^UTILITY(U,$J,358.3,44040,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,44040,1,3,0)
 ;;=3^Acrodermatitis Continua
 ;;^UTILITY(U,$J,358.3,44040,1,4,0)
 ;;=4^L40.2
 ;;^UTILITY(U,$J,358.3,44040,2)
 ;;=^5009162
 ;;^UTILITY(U,$J,358.3,44041,0)
 ;;=L40.3^^170^2116^20
 ;;^UTILITY(U,$J,358.3,44041,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,44041,1,3,0)
 ;;=3^Pustulosis Palmaris et Plantaris
 ;;^UTILITY(U,$J,358.3,44041,1,4,0)
 ;;=4^L40.3
 ;;^UTILITY(U,$J,358.3,44041,2)
 ;;=^5009163
 ;;^UTILITY(U,$J,358.3,44042,0)
 ;;=L40.4^^170^2116^5
 ;;^UTILITY(U,$J,358.3,44042,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,44042,1,3,0)
 ;;=3^Guttate Psoriasis
 ;;^UTILITY(U,$J,358.3,44042,1,4,0)
 ;;=4^L40.4
 ;;^UTILITY(U,$J,358.3,44042,2)
 ;;=^5009164
 ;;^UTILITY(U,$J,358.3,44043,0)
 ;;=L40.8^^170^2116^18
 ;;^UTILITY(U,$J,358.3,44043,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,44043,1,3,0)
 ;;=3^Psoriasis,Other
 ;;^UTILITY(U,$J,358.3,44043,1,4,0)
 ;;=4^L40.8
 ;;^UTILITY(U,$J,358.3,44043,2)
 ;;=^271917
 ;;^UTILITY(U,$J,358.3,44044,0)
 ;;=L40.9^^170^2116^19
 ;;^UTILITY(U,$J,358.3,44044,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,44044,1,3,0)
 ;;=3^Psoriasis,Unspec
 ;;^UTILITY(U,$J,358.3,44044,1,4,0)
 ;;=4^L40.9
 ;;^UTILITY(U,$J,358.3,44044,2)
 ;;=^5009171
 ;;^UTILITY(U,$J,358.3,44045,0)
 ;;=L57.0^^170^2116^2
 ;;^UTILITY(U,$J,358.3,44045,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,44045,1,3,0)
 ;;=3^Actinic Keratosis
 ;;^UTILITY(U,$J,358.3,44045,1,4,0)
 ;;=4^L57.0
 ;;^UTILITY(U,$J,358.3,44045,2)
 ;;=^66900
 ;;^UTILITY(U,$J,358.3,44046,0)
 ;;=L97.911^^170^2116^16
 ;;^UTILITY(U,$J,358.3,44046,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,44046,1,3,0)
 ;;=3^Non-Prs Chr Ulc,Rt Low Leg,Limited to Brkdwn Skin
 ;;^UTILITY(U,$J,358.3,44046,1,4,0)
 ;;=4^L97.911
 ;;^UTILITY(U,$J,358.3,44046,2)
 ;;=^5133679
 ;;^UTILITY(U,$J,358.3,44047,0)
 ;;=L97.912^^170^2116^12
 ;;^UTILITY(U,$J,358.3,44047,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,44047,1,3,0)
 ;;=3^Non-Prs Chr Ulc,Rt Low Leg w/ Fat Layer Exposed
 ;;^UTILITY(U,$J,358.3,44047,1,4,0)
 ;;=4^L97.912
 ;;^UTILITY(U,$J,358.3,44047,2)
 ;;=^5133681
 ;;^UTILITY(U,$J,358.3,44048,0)
 ;;=L97.913^^170^2116^13
 ;;^UTILITY(U,$J,358.3,44048,1,0)
 ;;=^358.31IA^4^2
